Featured Research

from universities, journals, and other organizations

Gynecologist disputes findings from global study of ovarian cancer

Date:
October 15, 2010
Source:
St. Joseph's Hospital and Medical Center
Summary:
A gynecologic oncologist is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

Related Articles


Published in The Lancet last month, the study reported that women who received early chemotherapy for a recurrence of ovarian cancer did not live longer than those whose treatment is delayed.

"While this study is a bold challenge to the assumption of early treatment, there are several significant problems with the findings," says Bradley Monk, MD, and a leader in developing new approaches to cancer treatments. "Our focus should no longer be on standard chemotherapy, but on targeted genetics-based treatments."

Dr. Monk expressed his concerns about the ovarian cancer study in an editorial in The Lancet. He and Dr. Robert Morris, of Wayne State University, wrote that finding the relevant therapy is far more important than timing when treating ovarian cancer. "The most troubling problem with the trial is that contemporary therapies were not available to most of the participants," says Dr. Monk. "This lack of availability is related not only to the chronological length of the trial (which started in 1996), but also to regulatory and financial barriers restricting access to all active compounds in the participating countries."

In the study, survival rates were not significantly different between those who started chemotherapy once a higher concentration of cancer-related proteins were detected and those whose treatment was delayed until they had clinical symptoms.

A total of 1,442 women from 59 centers around the world registered for the trial, and 529 were randomly assigned to treatment groups. About 70 percent of the women died. Of the 370 deaths, 186 occurred in the early treatment group and 184 in the delayed treatment. Median survival was 25.7 months for those on early treatment and 27.1 months for those on delayed treatment.


Story Source:

The above story is based on materials provided by St. Joseph's Hospital and Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert T Morris, Bradley J Monk. Ovarian cancer: relevant therapy, not timing, is paramount. The Lancet, 2010; 376 (9747): 1120 DOI: 10.1016/S0140-6736(10)61515-2

Cite This Page:

St. Joseph's Hospital and Medical Center. "Gynecologist disputes findings from global study of ovarian cancer." ScienceDaily. ScienceDaily, 15 October 2010. <www.sciencedaily.com/releases/2010/10/101015150933.htm>.
St. Joseph's Hospital and Medical Center. (2010, October 15). Gynecologist disputes findings from global study of ovarian cancer. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2010/10/101015150933.htm
St. Joseph's Hospital and Medical Center. "Gynecologist disputes findings from global study of ovarian cancer." ScienceDaily. www.sciencedaily.com/releases/2010/10/101015150933.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins